CRBU (Caribou Biosciences) Ending Cash Position: $26.19 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CRBU Caribou Biosciences Inc CRBU
61 GF Score
Price $1.30
GF Value $1.45
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Caribou Biosciences Ending Cash Position?

Caribou Biosciences CRBU 61 Ending Cash Position is $26.19 Mil as of Jun. 2026. GuruFocus rates CRBU with a GF Score™ of 61/100 and a GF Value™ of $1.45 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Caribou Biosciences's Ending Cash Position for the quarter that ended in Jun. 2026 was $26.19 Mil.

Caribou Biosciences's quarterly Ending Cash Position declined from Dec. 2025 ($12.36 Mil) to Mar. 2026 ($12.06 Mil) but then increased from Mar. 2026 ($12.06 Mil) to Jun. 2026 ($26.19 Mil).

Caribou Biosciences's annual Ending Cash Position declined from Dec. 2023 ($51.16 Mil) to Dec. 2024 ($16.29 Mil) and declined from Dec. 2024 ($16.29 Mil) to Dec. 2025 ($12.36 Mil).

Caribou Biosciences Ending Cash Position Related Terms

Caribou Biosciences Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Caribou Biosciences's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Caribou Biosciences Ending Cash Position Chart

Caribou Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 240.42 58.34 51.16 16.29 12.36

Caribou Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.20 11.14 12.36 12.06 26.19
CRBU
61GF Score
Caribou Biosciences Inc CRBU
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Caribou Biosciences Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Caribou Biosciences's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=16.293+-3.933
=12.36

Caribou Biosciences's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=12.103+14.091
=26.19

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $26.19 Mil mean?
Caribou Biosciences (CRBU) has a Ending Cash Position of $26.19 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Caribou Biosciences and its competitors.
Is Caribou Biosciences' Ending Cash Position too high?
Caribou Biosciences' current Ending Cash Position is $26.19 Mil. Overall, Caribou Biosciences has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Caribou Biosciences' Ending Cash Position compare to CDXS and SPRB?
Caribou Biosciences' Ending Cash Position of $26.19 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Caribou Biosciences and its competitors. Caribou Biosciences's current Ending Cash Position is $26.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caribou Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Caribou Biosciences (CRBU) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.45, compared to a current price of $1.30 — trading 10.3% below its estimated fair value. The current Ending Cash Position is $26.19 Mil. Caribou Biosciences' overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Caribou Biosciences (CRBU), the current Ending Cash Position is $26.19 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Caribou Biosciences (CRBU) Overvalued in 2026?

Based on GuruFocus' analysis, Caribou Biosciences stock appears to be undervalued. The current stock price of $1.30 is trading 10.3% below its estimated GF Value™ of $1.45. GuruFocus considers Caribou Biosciences to be Modestly Undervalued.

Key valuation signals for CRBU:

  • Ending Cash Position: $26.19 Mil
  • GF Value™: $1.45 vs. price of $1.30 (10.3% below fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the CRBU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Caribou Biosciences Business Description

Address 2929 7th Street, Suite 105, Berkeley, CA, USA, 94710
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
61GF Score

Get the complete analysis for CRBU

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.30
Price
$1.45
GF Value